LOL - TDAmeritrade | NAVB Message Board Posts


Navidea Biopharmaceuticals, Inc.

  NAVB website

NAVB   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  37780 of 38601  at  8/16/2022 2:55:00 PM  by

Riskcheck


 In response to msg 37775 by  LVoptimist
view thread

Re: LOL - TDAmeritrade

Everyone has a different approach to viewing their investment into this rights offering. Each investor weighs the risk and exposure based on their confidence in the company and its value proposition.

For me, Ive been in since before they parted ways with Neoprobe Corporation and traded under NEOP, watching my investment climb and crash too many times to really justify my long term investment. Management seemed to always be on the brink of putting the pieces together, and then another blunder in leadership hubris fueled their arrogance and magnified their business finance ignorance.

I see the rights offering as structured, as an opportunity to average my 6 figure investment to a lower share cost, such that at a $300M valuation I can break even. The company, from outside appearances, is advancing its IP assets while maintaining its loss carry forward, and not gambling in another risky credit vehicle that could undermine their survival.

Anyone who invests in a biotech knows each investment is unique, and either an educated risk or impulsive gamble. Usually its the gamblers that do the most bitching when they cant see beyond the SP performance. I wish everyone success in their decision, whether its to participate or observe.👍


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 5  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
37784 Re: LOL - TDAmeritrade LVoptimist 0 8/16/2022 4:28:36 PM




Financial Market Data provided by
.
Loading...